Author:
Bleavins Michael R.,Carini Claudio,Jurima-Romet Malle,Rahbari Ramin
Reference28 articles.
1. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework;Clin. Pharmacol. Ther.,2001
2. A cost-effective approach to the qualification and acceptance of biomarkers;Williams;Nature Rev. Drug Dis.,2006
3. The price of innovation: New estimates of drug development costs;DiMasi;J. Health Econ.,2003
4. Cost estimates;Chem. Eng. News,2003
5. Understanding the strategic importance of biomarkers for discovery and early development phases;Hurko;Drug Disc. World,2006